The rationale of pharmacoeconomic analysis in rheumatologic indications.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Clinical and Experimental Rheumatology

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Economics

• Identifiers
  PMID 23072796
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Systematic literature review on economic implications and pharmacoeconomic issues of rheumatoid arthritis.

  2012cited by this paper
• Economic benefits of optimizing anchor therapy for rheumatoid arthritis.

  2012cited by this paper
• The economic impact of gout: a systematic literature review.

  2012cited by this paper
• Chapter 18 – Physiological and Laboratory Markers of Drug Effect

  2012cited by this paper
• Systemic vasculitis: how little we know about their societal and economic burden.

  2012cited by this paper
• Systematic literature review on economic implications and pharmacoeconomic issues of psoriatic arthritis.

  2012cited by this paper
• A systematic literature review of the economic impact of ankylosing spondylitis.

  2012cited by this paper
• Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets.

  2012cited by this paper
• Economic evaluation of da Vinci-assisted robotic surgery: a systematic review

  2012cited by this paper
• Systemic lupus erythematosus and the economic perspective: a systematic literature review and points to consider.

  2012cited by this paper
• Treat-to-target in systemic lupus erythematosus: where are we today?

  2012cited by this paper
• Development of quality indicators to evaluate the monitoring of SLE patients in routine clinical practice.

  2011cited by this paper
• Surrogate outcomes are associated with low methodological quality of studies of rheumatoid arthritis treated with antitumour necrosis factor agents: a systematic review

  2011cited by this paper
• Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)

  2011cited by this paper
• Analysis of Drug and Administrative Costs Allowed by U.S. Private and Public Third-Party Payers for 3 Intravenous Biologic Agents for Rheumatoid Arthritis

  2011cited by this paper
• Assessing the cost-effectiveness of biologic agents for the management of moderate-to-severe rheumatoid arthritis in anti-TNF inadequate responders in Italy: a modelling approach.

  2011cited by this paper
• A clinician's critique of rheumatoid arthritis health economic models.

  2011cited by this paper
• Modelling the cost-effectiveness of biologic treatments for psoriatic arthritis.

  2011cited by this paper
• The cost of care of rheumatoid arthritis and ankylosing spondylitis patients in tertiary care rheumatology units in Turkey.

  2011cited by this paper
• Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus

  2010cited by this paper
• Qual Life Res (2010) 19:875–886 DOI 10.1007/s11136-010-9648-y ORIGINAL PAPER Development of the EQ-5D-Y: a child-friendly version of the EQ-5D

  2010cited by this paper
• Feasibility, reliability, and validity of the EQ-5D-Y: results from a multinational study

  2010cited by this paper
• Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA Study

  2010cited by this paper
• Canadian Agency for Drugs and Technologies in Health

  2009cited by this paper
• Health technology assessment

  2009cited by this paper
• Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura.

  2009cited by this paper
• Cost-of-illness of rheumatoid arthritis and ankylosing spondylitis.

  2009cited by this paper
• The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy

  2008cited by this paper
• Decision modelling for health economic evaluation

  2007cited by this paper
• Thoughts on health economics in rheumatoid arthritis

  2007cited by this paper
• The burden of rheumatoid arthritis and access to treatment: health burden and costs

  2007influential reference
• Problems faced at work due to inflammatory arthritis: new insights gained from understanding patients' perspective.

  2007cited by this paper
• Systematic review of studies of productivity loss due to rheumatoid arthritis.

  2006cited by this paper
• Costs and course of disease and function in early rheumatoid arthritis: a 3-year follow-up (the Swedish TIRA project).

  2006cited by this paper
• Health economics: implications for novel antirheumatic therapies

  2005cited by this paper
• Indirect cost assessment in patients with rheumatoid arthritis (RA): comparison of data from the health economic patient questionnaire HEQ-RA and insurance claims data.

  2005cited by this paper
• Cost-effectiveness of anti-tumor necrosis factor agents.

  2004cited by this paper
• The evolving use of tumor necrosis factor inhibitors in rheumatoid arthritis.

  2004cited by this paper
• Rheumatoid arthritis: direct and indirect costs.

  2004cited by this paper
• Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies.

  2003cited by this paper
• The new subjective medicine: taking the patient's point of view on health care and health.

  2003cited by this paper
• Methodological issues in the monetary valuation of benefits in healthcare

  2003cited by this paper
• Health Economics: An Introduction to Economic Evaluation

  2002cited by this paper
• Decision validity should determine whether a generic or condition-specific HRQOL measure is used in health care decisions.

  2002cited by this paper
• Quality of life measurement: bibliographic study of patient assessed health outcome measures

  2002cited by this paper
• Development of a matrix of cost domains in economic evaluation of rheumatoid arthritis.

  2001cited by this paper
• The costs of rheumatoid arthritis: an international long-term view.

  2000cited by this paper
• Measuring health-related quality of life.

  1999cited by this paper
• Cost?Benefit Analysis and Environmental Policy

  1998cited by this paper
• Modelling in economic evaluation: an unavoidable fact of life.

  1997cited by this paper
• A social tariff for EuroQol: results from a UK general population survey

  1995cited by this paper
• The friction cost method for measuring indirect costs of disease.

  1995cited by this paper
• Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis.

  1994cited by this paper
• Measuring Health-Related Quality of Life

  1993cited by this paper
• The MOS 36‐Item Short‐Form Health Survey (SF‐36): II. Psychometric and Clinical Tests of Validity in Measuring Physical and Mental Health Constructs

  1993cited by this paper
• The MOS 36-Item Short-Form Health Survey (SF-36)

  1992cited by this paper
• The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection

  1992cited by this paper
• EuroQol : a new facility for the measurement of health-related quality of life

  1990influential reference
• Reducing the incidence of infection after caesarean section: implications of prophylaxis with antibiotics for hospital resources.

  1989cited by this paper
• Methods for the economic evaluation of health care programmes

  1987cited by this paper
• Measurement of health state utilities for economic appraisal.

  1986cited by this paper
• The arthritis impact measurement scales. Further investigations of a health status measure.

  1982cited by this paper
• Foundations of cost-effectiveness analysis for health and medical practices.

  1977cited by this paper

• Pharmacoepigenetics of Rheumatic Disorders

  2019cites this paper
• Rare diseases under different levels of economic analysis: current activities, challenges and perspectives

  2018cites this paper
• Optimization of biological therapy in rheumatoid arthritis patients: outcomes from the CREATE registry after 2 years of follow-up

  2017cites this paper
• Efectividad y eficiencia de la terapia biológica en artritis reumatoide en la práctica clínica habitual

  2017cites this paper
• Effectiveness and healthcare costs among stabilised rheumatoid arthritis patients with dose reduction of adalimumab or etanercept in real world.

  2017cites this paper
• Real-world cost-effectiveness of infliximab, etanercept and adalimumab in rheumatoid arthritis patients: results of the CREATE registry

  2016cites this paper
• Cost-effectiveness of clinical remission by treat to target strategy in established rheumatoid arthritis: results of the CREATE registry

  2016cites this paper
• BUDGET IMPACT ANALYSIS OF BELIMUMAB IN TREATING SYSTEMIC LUPUS ERYTHEMATOSUS

  2016cites this paper
• Health economic models in hemophilia A and utility assumptions from a clinician's perspective

  2015influential citation
• Assessment of the Economic Impact of Belimumab for the Treatment of Systemic Lupus Erythematosus in the Italian Setting: A Cost-Effectiveness Analysis

  2015cites this paper
• Why Effectiveness of Robot-Mediated Neurorehabilitation Does Not Necessarily Influence Its Adoption

  2014cites this paper
• Cost for Tuberculosis Care in Developed Countries: Which Data for an Economic Evaluation?

  2014cites this paper
• Embitterment in patients with a rheumatic disease after a disability pension examination: occurrence and potential determinants.

  2014cites this paper
• Health Technology Assessment of Belimumab: A New Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus

  2014cites this paper
• Acceptability of robotic technology in neuro-rehabilitation: Preliminary results on chronic stroke patients

  2014cites this paper
• The social cost of rheumatoid arthritis in Italy: the results of an estimation exercise.

  2014cites this paper
• Analisi di budget impact sull ’ utilizzo di paracalcitolo nel trattamento dell ’ iperparatiroidismo secondario associato a malattia renale cronica Budget impact analysis of the use of paricalcitol for the treatment of secondary hyperparathyroidism in chronic kidney disease

  2014cites this paper
• Long-term costs and outcomes in psoriatic arthritis patients not responding to conventional therapy treated with tumour necrosis factor inhibitors: the extension of the Psoriatic Arthritis Cost Evaluation (PACE) study.

  2013cites this paper
• The economic impact of gout: a systematic literature review.

  2012cites this paper
• Systematic literature review on economic implications and pharmacoeconomic issues of psoriatic arthritis.

  2012cites this paper
• Systemic vasculitis: how little we know about their societal and economic burden.

  2012cites this paper
• Treat-to-target in systemic lupus erythematosus: where are we today?

  2012cites this paper
• A systematic literature review of the economic impact of ankylosing spondylitis.

  2012cites this paper
• Systemic lupus erythematosus and the economic perspective: a systematic literature review and points to consider.

  2012cites this paper
• Systematic literature review on economic implications and pharmacoeconomic issues of rheumatoid arthritis.

  2012cites this paper
• Clinicoeconomics and Outcomes Research Dovepress Costs Associated with Rheumatoid Arthritis in Italy: Past, Present, and Future

  year unknowncites this paper